On October 7, 2026, Barclays started coverage of Humacyte Inc (HUMA) at Equal-Weight.
Among two firms active over the past 90 days, one holds a bullish rating. Eight analysts set consensus price targets as of October 30, 2026, with a mean of $1.66, a median of $1.15 and a range of $0.51 to $4.20.
For Q4 FY2026, analysts expect EPS of -$0.09 and revenue of $1.87 million. The next earnings report is scheduled for November 10, 2026 (confirmed).
